The current pillars of quadruple heart failure therapy include angiotensin receptor—neprilysin inhibitors (ARNI), beta blocker, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and mineralocorticoid receptor antagonists (MRA), all of which reduce mortality. This evidence concerns the gene NR3C2 and heart failure.